Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The latest projects newly into human trials include BNT3212.
But results come from a curated dataset, with no in-trial comparator.
A common mutation comes into play for PRMT5 inhibition.
Tolerability could decide first-line therapy in EGFRm disease.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
